论文部分内容阅读
管光地:常山之生药研究常山治疟初步研究报告(7—21页)中国特效药研究所印行(1944)内容摘要——作者在1942年研究常山根的生药学,得出结论如次:1)常山种类虽多,似当以 Dich-roa febrifuga Lour.为正品,而先加以研究,然后再及他种。2)本草谓蜀漆(苗)与常山功效相同,似当以其茎叶作相同研究,如能证明其功效相同。则可增加产量,因现在只用根部而不用茎叶,如全部植物供用,则其产量增加不止一倍。考之外国生药如其药用部分为根,然当提取成分供用时,亦往往并用其它部分以少损失。
GUAN Guangdi: Preliminary Research Report on Changshan for the Study of Crude Drugs of Changshan for Malaria (pages 7-21) China Institute of Pharmacopoeia (1944) Abstract—The author studied Changshangen’s pharmacopeia in 1942 and reached the following conclusions: 1) Although there are many types of Changshan, it seems that Dich-roa febrifuga Lour. is genuine, and it should be studied first, and then be planted again. 2) Materia Medica said that the lacquer (seedling) has the same efficacy as Changshan, and it seems that the same research should be conducted on stems and leaves. If it can prove the same effect. The yield can be increased because now only the roots are used instead of stems and leaves. If all the plants are used, the output will increase more than double. Exogenous medicines outside the country are rooted in their medicinal parts. However, when extracting ingredients for use, they are often combined with other parts with less loss.